{"id":69123,"date":"2026-04-10T10:03:11","date_gmt":"2026-04-10T04:33:11","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=69123"},"modified":"2026-04-10T10:03:13","modified_gmt":"2026-04-10T04:33:13","slug":"ajanta-pharma-q4-results-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/","title":{"rendered":"Ajanta Pharma Q4 Results 2026: Date, Revenue, PAT &#038; Analyst Outlook"},"content":{"rendered":"<p>Ajanta Pharma (NSE: AJANTPHARM) is preparing to announce its Q4 FY26 financial results for the period ended March 31, 2026. The board of directors is scheduled to meet on May 2026 (Expected) to approve the audited statements and consider a final dividend recommendation. With the stock at Rs 2,900 \u2014 against a 52-week high of Rs 3,600 and 1-year return of -14% \u2014 the Q4 FY26 results will be a pivotal event for investors.<\/p><p>Analyst estimates for Q4 FY26 revenue stand at Rs 1,200-1,300 Cr, with PAT expectations of Rs 268-295 Cr and margin projections of EBITDA 32-34%. This article covers the Ajanta Pharma Q4 results 2026 date, earnings estimates, five key performance factors, five risks, analyst ratings, and investor FAQs.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/#Ajanta_Pharma_Q4_Results_2026_Date\" title=\"Ajanta Pharma Q4 Results 2026 Date\">Ajanta Pharma Q4 Results 2026 Date<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/#Why_This_Quarter_Matters\" title=\"Why This Quarter Matters\">Why This Quarter Matters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/#Ajanta_Pharma_Q4_FY26_Earnings_Estimates\" title=\"Ajanta Pharma Q4 FY26 Earnings Estimates\">Ajanta Pharma Q4 FY26 Earnings Estimates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/#5_Key_Factors_That_Will_Drive_Ajanta_Pharma_Q4_FY26_Performance\" title=\"5 Key Factors That Will Drive Ajanta Pharma Q4 FY26 Performance\">5 Key Factors That Will Drive Ajanta Pharma Q4 FY26 Performance<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/#Revenue_Momentum\" title=\"Revenue Momentum\">Revenue Momentum<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/#Margin_Trajectory\" title=\"Margin Trajectory\">Margin Trajectory<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/#PAT_Quality\" title=\"PAT Quality\">PAT Quality<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/#Management_Guidance_for_FY27\" title=\"Management Guidance for FY27\">Management Guidance for FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/#Dividend_Declaration\" title=\"Dividend Declaration\">Dividend Declaration<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/#5_Risks_to_Watch_in_Ajanta_Pharma_Q4_FY26\" title=\"5 Risks to Watch in Ajanta Pharma Q4 FY26\">5 Risks to Watch in Ajanta Pharma Q4 FY26<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/#US_Tariff_and_Macro_Headwinds\" title=\"US Tariff and Macro Headwinds\">US Tariff and Macro Headwinds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/#Earnings_Miss_Risk\" title=\"Earnings Miss Risk\">Earnings Miss Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/#FY27_Guidance_Below_Consensus\" title=\"FY27 Guidance Below Consensus\">FY27 Guidance Below Consensus<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/#FII_Outflow_Continuation\" title=\"FII Outflow Continuation\">FII Outflow Continuation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/#Sector_Regulatory_Risk\" title=\"Sector Regulatory Risk\">Sector Regulatory Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/#Ajanta_Pharma_Share_Price_and_Analyst_Ratings\" title=\"Ajanta Pharma Share Price and Analyst Ratings\">Ajanta Pharma Share Price and Analyst Ratings<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/#What_is_the_Ajanta_Pharma_Q4_results_2026_date\" title=\"What is the Ajanta Pharma Q4 results 2026 date?\">What is the Ajanta Pharma Q4 results 2026 date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/#What_is_the_Ajanta_Pharma_Q4_FY26_PAT_estimate\" title=\"What is the Ajanta Pharma Q4 FY26 PAT estimate?\">What is the Ajanta Pharma Q4 FY26 PAT estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/#What_is_Ajanta_Pharmas_share_price_ahead_of_Q4_results\" title=\"What is Ajanta Pharma&#8217;s share price ahead of Q4 results?\">What is Ajanta Pharma&#8217;s share price ahead of Q4 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/#Will_Ajanta_Pharma_declare_a_dividend_in_Q4_FY26\" title=\"Will Ajanta Pharma declare a dividend in Q4 FY26?\">Will Ajanta Pharma declare a dividend in Q4 FY26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/#Which_analysts_have_a_Buy_rating_on_Ajanta_Pharma\" title=\"Which analysts have a Buy rating on Ajanta Pharma?\">Which analysts have a Buy rating on Ajanta Pharma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/#What_were_Ajanta_Pharma_Q3_FY26_results\" title=\"What were Ajanta Pharma Q3 FY26 results?\">What were Ajanta Pharma Q3 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/#When_do_TCS_and_Infosys_announce_Q4_results_2026\" title=\"When do TCS and Infosys announce Q4 results 2026?\">When do TCS and Infosys announce Q4 results 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/#Is_Ajanta_Pharma_a_good_investment_ahead_of_Q4_results\" title=\"Is Ajanta Pharma a good investment ahead of Q4 results?\">Is Ajanta Pharma a good investment ahead of Q4 results?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-q4-results-2026\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Ajanta_Pharma_Q4_Results_2026_Date\"><\/span><strong>Ajanta Pharma Q4 Results 2026 Date<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Get free investment predictions and live Q4 result alerts on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Company<\/strong><\/td><td><strong>Results Date<\/strong><\/td><td><strong>Article<\/strong><\/td><\/tr><tr><td>TCS<\/td><td>April 9, 2026<\/td><td>Preview on Univest<\/td><\/tr><tr><td>Infosys<\/td><td>April 23, 2026<\/td><td>Preview on Univest<\/td><\/tr><tr><td>Ajanta Pharma<\/td><td>May 2026 (Expected)<\/td><td>This article<\/td><\/tr><\/tbody><\/table><\/figure><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_This_Quarter_Matters\"><\/span><strong>Why This Quarter Matters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Ajanta Pharma enters Q4 FY26 with expectations of 8-12% YoY revenue growth. Q4 determines full-year FY26 performance, sets FY27 estimate baselines, and triggers final dividend announcements. At a 1-year return of -14%, this quarter&#8217;s results and FY27 guidance will be critical for determining stock trajectory.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Ajanta_Pharma_Q4_FY26_Earnings_Estimates\"><\/span><strong>Ajanta Pharma Q4 FY26 Earnings Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"931\" height=\"486\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/10095733\/image-473.jpeg\" alt=\"Ajanta Pharma Q4 FY26 analyst estimates. Source: MOFSL, YES Securities, JM Financial.\" class=\"wp-image-69128\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/10095733\/image-473.jpeg 931w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/10095733\/image-473-300x157.jpeg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/10095733\/image-473-768x401.jpeg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/10095733\/image-473-900x470.jpeg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/10095733\/image-473-600x313.jpeg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/10095733\/image-473-150x78.jpeg 150w\" sizes=\"(max-width: 931px) 100vw, 931px\" \/><\/figure><p>Access premium SEBI-registered research on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Metric<\/strong><\/td><td><strong>Q3 FY26 Actual<\/strong><\/td><td><strong>Q4 FY26 Estimate<\/strong><\/td><td><strong>Driver<\/strong><\/td><\/tr><tr><td>Revenue<\/td><td>Rs 1,110 Cr<\/td><td>Rs 1,200-1,300 Cr<\/td><td>Volume + pricing<\/td><\/tr><tr><td>PAT<\/td><td>Rs 248 Cr<\/td><td>Rs 268-295 Cr<\/td><td>Operating leverage<\/td><\/tr><tr><td>Margin<\/td><td>EBITDA 32.8%<\/td><td>EBITDA 32-34%<\/td><td>Cost control<\/td><\/tr><tr><td>Key Growth Metric<\/td><td>Q3 trend<\/td><td>8-12% YoY revenue growth<\/td><td>Management execution<\/td><\/tr><tr><td>Dividend Estimate<\/td><td>\u2014<\/td><td>Rs 28-36 per share<\/td><td>Board recommendation<\/td><\/tr><\/tbody><\/table><\/figure><p>Screen <a href=\"https:\/\/univest.in\/screeners\">Ajanta Pharma fundamentals<\/a> on <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Key_Factors_That_Will_Drive_Ajanta_Pharma_Q4_FY26_Performance\"><\/span><strong>5 Key Factors That Will Drive Ajanta Pharma Q4 FY26 Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Revenue_Momentum\"><\/span><strong>Revenue Momentum<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analysts expect Rs 1,200-1,300 Cr in Q4 FY26 revenue versus Rs 1,110 Cr in Q3. Q4 is seasonally important for the Pharma sector and the ability to convert the pipeline into recognised revenue will be the first performance test.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Margin_Trajectory\"><\/span><strong>Margin Trajectory<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Q4 FY26 margin expectations are EBITDA 32-34% versus EBITDA 32.8% in Q3. Input cost trends, employee expenses, and pricing power will determine whether the company can sustain or improve on Q3 levels.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"PAT_Quality\"><\/span><strong>PAT Quality<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Net profit is estimated at Rs 268-295 Cr. Investors will assess whether PAT is driven by operational improvement or non-recurring items. A clean recurring profit print is most positively received by institutional investors.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Management_Guidance_for_FY27\"><\/span><strong>Management Guidance for FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The most consequential output will be FY27 guidance \u2014 revenue growth bands, margin targets, and capex plans. Credible FY27 guidance carries significant weight for re-rating potential in the current macro environment.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Dividend_Declaration\"><\/span><strong>Dividend Declaration<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Ajanta Pharma is expected to consider a final dividend of Rs 28-36 per share. The quantum signals management&#8217;s confidence in free cash flow generation and sets expectations for FY27 capital allocation.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Risks_to_Watch_in_Ajanta_Pharma_Q4_FY26\"><\/span><strong>5 Risks to Watch in Ajanta Pharma Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"US_Tariff_and_Macro_Headwinds\"><\/span><strong>US Tariff and Macro Headwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The 26% US reciprocal tariff on Indian goods has created macro uncertainty. For Ajanta Pharma, indirect impacts include FII outflows and earnings estimate cuts if global demand slows.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Earnings_Miss_Risk\"><\/span><strong>Earnings Miss Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>If Ajanta Pharma&#8217;s Q4 FY26 results miss estimates, the stock could correct sharply. Investors should monitor revenue versus Rs 1,200-1,300 Cr and PAT versus Rs 268-295 Cr as the two primary watchpoints.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FY27_Guidance_Below_Consensus\"><\/span><strong>FY27 Guidance Below Consensus<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>If FY27 guidance falls below Street expectations, the stock may decline even if Q4 numbers are in line. Forward guidance carries more weight than the reported quarter currently.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FII_Outflow_Continuation\"><\/span><strong>FII Outflow Continuation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>FIIs sold Rs 22,000 crore in Indian equities in a single week following the tariff announcement. Continued selling creates headwinds for Ajanta Pharma regardless of fundamentals.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Sector_Regulatory_Risk\"><\/span><strong>Sector Regulatory Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The Pharma sector faces evolving regulatory frameworks. Policy changes that increase compliance costs or alter competitive dynamics could affect Ajanta Pharma&#8217;s profitability.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Ajanta_Pharma_Share_Price_and_Analyst_Ratings\"><\/span><strong>Ajanta Pharma Share Price and Analyst Ratings<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/10095953\/Ajanta-Pharma-share-price-snapshot-and-analyst-ratings-1024x536.jpg\" alt=\"Ajanta Pharma share price snapshot and analyst ratings. Source Brokerages, NSE data.\" class=\"wp-image-69130\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/10095953\/Ajanta-Pharma-share-price-snapshot-and-analyst-ratings-1024x536.jpg 1024w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/10095953\/Ajanta-Pharma-share-price-snapshot-and-analyst-ratings-300x157.jpg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/10095953\/Ajanta-Pharma-share-price-snapshot-and-analyst-ratings-768x402.jpg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/10095953\/Ajanta-Pharma-share-price-snapshot-and-analyst-ratings-900x471.jpg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/10095953\/Ajanta-Pharma-share-price-snapshot-and-analyst-ratings-600x314.jpg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/10095953\/Ajanta-Pharma-share-price-snapshot-and-analyst-ratings-150x79.jpg 150w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/10095953\/Ajanta-Pharma-share-price-snapshot-and-analyst-ratings.jpg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><p>Ajanta Pharma is trading at Rs 2,900 as of early April 2026, against a 52-week high of Rs 3,600 and 52-week low of Rs 2,400. Market cap stands at Rs 25,600 Cr.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Brokerage<\/strong><\/td><td><strong>Rating<\/strong><\/td><td><strong>Target Price<\/strong><\/td><td><strong>Thesis<\/strong><\/td><\/tr><tr><td>MOFSL<\/td><td>Buy<\/td><td>Rs 3,500<\/td><td>Branded generics Africa + Asia + India<\/td><\/tr><tr><td>YES Securities<\/td><td>Buy<\/td><td>Rs 3,400<\/td><td>Cardiology + ophthalmology branded<\/td><\/tr><tr><td>JM Financial<\/td><td>Add<\/td><td>Rs 3,250<\/td><td>Africa institution + branded mix<\/td><\/tr><tr><td>Emkay<\/td><td>Buy<\/td><td>Rs 3,300<\/td><td>High margin; consistent earnings growth<\/td><\/tr><\/tbody><\/table><\/figure><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Ajanta Pharma live and receive real-time Q4 result alerts.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Ajanta Pharma Q4 FY26 results on May 2026 (Expected) will be a key event for Pharma sector investors. Analysts project PAT of Rs 268-295 Cr and revenue of Rs 1,200-1,300 Cr. At Rs 2,900 with analyst targets from Rs 3,300 to Rs 3,500, FY27 guidance will be the most critical post-results catalyst.<\/p><p>For more Q4 FY26 previews, visit <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Ajanta_Pharma_Q4_results_2026_date\"><\/span><strong>What is the Ajanta Pharma Q4 results 2026 date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The Ajanta Pharma Q4 results 2026 date is May 2026 (Expected). The board will meet to approve audited Q4 FY26 financials and consider a final dividend recommendation.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Ajanta_Pharma_Q4_FY26_PAT_estimate\"><\/span><strong>What is the Ajanta Pharma Q4 FY26 PAT estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analysts estimate Ajanta Pharma Q4 FY26 PAT at Rs 268-295 Cr, based on revenue of Rs 1,200-1,300 Cr and margin of EBITDA 32-34%.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_Ajanta_Pharmas_share_price_ahead_of_Q4_results\"><\/span>What is Ajanta Pharma&#8217;s share price ahead of Q4 results?<span class=\"ez-toc-section-end\"><\/span><\/h3><p>Ajanta Pharma is trading at Rs 2,900. The 52-week high is Rs 3,600 and low is Rs 2,400. The 1-year return is -14% and market cap is Rs 25,600 Cr.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Will_Ajanta_Pharma_declare_a_dividend_in_Q4_FY26\"><\/span><strong>Will Ajanta Pharma declare a dividend in Q4 FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Ajanta Pharma is expected to consider a final dividend of Rs 28-36 per share at the Q4 FY26 board meeting on May 2026 (Expected).<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Which_analysts_have_a_Buy_rating_on_Ajanta_Pharma\"><\/span><strong>Which analysts have a Buy rating on Ajanta Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>MOFSL (Buy, Rs 3,500), YES Securities (Buy, Rs 3,400), JM Financial (Add, Rs 3,250), Emkay (Buy, Rs 3,300) have positive ratings heading into Q4 FY26.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_were_Ajanta_Pharma_Q3_FY26_results\"><\/span><strong>What were Ajanta Pharma Q3 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Ajanta Pharma reported Q3 FY26 revenue of Rs 1,110 Cr and PAT of Rs 248 Cr, with margin at EBITDA 32.8%.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"When_do_TCS_and_Infosys_announce_Q4_results_2026\"><\/span><strong>When do TCS and Infosys announce Q4 results 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>TCS declared Q4 FY26 results on April 9, 2026. Infosys Q4 FY26 results are scheduled for April 23, 2026. Read both previews on Univest Blogs.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Is_Ajanta_Pharma_a_good_investment_ahead_of_Q4_results\"><\/span><strong>Is Ajanta Pharma a good investment ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>This depends on your risk appetite. Ajanta Pharma has compelling long-term factors alongside genuine near-term risks. Consult a SEBI-registered financial advisor before investing.<\/p><p><strong>Disclaimer: <\/strong>Investment in the share market is subject to risk. This article is for informational and educational purposes only. All financial data and analyst estimates are sourced from publicly available information. Verify before investing. Consult a SEBI-registered advisor before making investment decisions.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/upl-q4-results-2026\">UPL Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/zee-entertainment-enterprises-q4-results-2026\">Zee Entertainment Enterprises Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/sun-tv-network-q4-results-2026\">Sun TV Network Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/sapphire-foods-india-q4-results-2026\">Sapphire Foods India Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/metro-brands-q4-results-2026\">Metro Brands Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Ajanta Pharma (NSE: AJANTPHARM) is preparing to announce its Q4 FY26 financial results for the period ended March 31, 2026. The board of directors is scheduled to meet on May 2026 (Expected) to approve the audited statements and consider a final dividend recommendation. With the stock at Rs 2,900 \u2014 against a 52-week high of<\/p>\n","protected":false},"author":28,"featured_media":69131,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3858],"class_list":["post-69123","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-q4-results"],"metadata":{"_edit_lock":["1775795739:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"amazonS3_cache":["a:6:{s:62:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-473.jpeg\";a:2:{s:2:\"id\";i:69128;s:11:\"source_type\";s:13:\"media-library\";}s:94:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/10095733\/image-473.jpeg\";a:2:{s:2:\"id\";i:69128;s:11:\"source_type\";s:13:\"media-library\";}s:106:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Ajanta-Pharma-share-price-snapshot-and-analyst-ratings.jpg\";a:2:{s:2:\"id\";i:69130;s:11:\"source_type\";s:13:\"media-library\";}s:115:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Ajanta-Pharma-share-price-snapshot-and-analyst-ratings-1024x536.jpg\";a:2:{s:2:\"id\";i:69130;s:11:\"source_type\";s:13:\"media-library\";}s:138:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/10095953\/Ajanta-Pharma-share-price-snapshot-and-analyst-ratings.jpg\";a:2:{s:2:\"id\";i:69130;s:11:\"source_type\";s:13:\"media-library\";}s:147:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/10095953\/Ajanta-Pharma-share-price-snapshot-and-analyst-ratings-1024x536.jpg\";a:2:{s:2:\"id\";i:69130;s:11:\"source_type\";s:13:\"media-library\";}}"],"rank_math_seo_score":["80"],"rank_math_primary_category":["842"],"rank_math_description":["Ajanta Pharma Q4 results May 2026 (Expected). PAT estimate Rs 268-295 Cr, margin EBITDA 32-34%. Full Q4 FY26 preview with analyst targets."],"rank_math_title":["Ajanta Pharma Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook"],"rank_math_focus_keyword":["Ajanta Pharma Q4 Results"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["69131"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["7720"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/10100102\/Ajanta-Pharma.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/69123","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=69123"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/69123\/revisions"}],"predecessor-version":[{"id":69132,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/69123\/revisions\/69132"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/69131"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=69123"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=69123"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=69123"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}